Clinical implications of fetuin-A

Peter Jirak(Paracelsus Medical University), Hermann Salmhofer(Paracelsus Medical University), Vera Paar(Paracelsus Medical University), Daniel Kretzschmar(Friedrich Schiller University Jena), Rudin Pistulli(Friedrich Schiller University Jena), Lars Stechemesser(Paracelsus Medical University), Bernhard Wernly(Paracelsus Medical University), Uta C. Hoppe(Baker Heart and Diabetes Institute), Michael Lichtenauer(Medical University of Vienna), Albert Topf(Paracelsus Medical University), Moritz Mirna(Paracelsus Medical University), Michael Franzen(Paracelsus Medical University), Elena Morè(Paracelsus Medical University)
Advances in clinical chemistry
January 1, 2019
10.1016/bs.acc.2018.12.003
Cited by 62

Related Papers

Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension
|Circulation|2011|569
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study
|The Lancet|2022|310
Virtual and augmented reality in critical care medicine: the patient’s, clinician’s, and researcher’s perspective
|Critical Care|2022|229
The impact of frailty on survival in elderly intensive care patients with COVID-19: the COVIP study
|Critical Care|2021|188
Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue
|International Journal of Obesity|2012|168